uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...
CSL Behring confirms long-term efficacy of HEMGENIX in hemophilia B treatment
Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...
MedPage Today2h
Gene Therapy May Be a Game Changer for Transfusion-Dependent Thalassemia
The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
UCSD Guardian11d
UCSD offers novel gene therapy for hemophilia B, a rare blood disorder
UC San Diego announced that it is offering a newly Food and Drug Administration-approved gene therapy for hemophilia B, a ...
BioSpace6h
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...
Gene therapy may be 'one-shot stop' for rare bone disease
For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...
hemophilianewstoday8h
Are hemophilia treatment centers in danger?
Federal funding ensures that hemophilia treatment centers can properly care for those with bleeding disorders, columnist Jennifer Lynne says.
Hemophilia Treatment Market Valuation is Projected to Reach US$ 21.48 Billion by 2033 | Astute Analytica
Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...